Beijing Scitop Bio-Tech Co., Ltd. Class A

Beijing Scitop Bio-Tech Co., Ltd. Class A

SSZSE:300858
12.98
CNY
-0.35
(-2.63%)
0.21EPS
72.05P/E
3.98BMarket Cap
Apr 28Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.1
2.18
1.74
1.91
1.85
1.78
1.64
1.65
1.12
1.16
1.39
1.42
Basic EPS, GAAP
0.4
0.1
0.44
0.55
0.56
0.51
0.49
0.49
0.35
0.36
0.36
0.21
Free Cash Flow per Basic Share
- -
- -
0.23
-0.04
0.31
0.24
0.19
0.29
-0.27
-0.26
-0.66
- -
Dividend per Share
0.02
0.28
0.13
0.42
- -
- -
0.37
0.33
0.2
0.15
0.15
- -
Book Value per Share
1.22
1.19
1.68
1.81
2.39
4.19
4.34
7.59
6.58
6.79
6.99
6.69
Tangible Book Value per Share
0.86
1.04
1.55
1.68
2.26
4.09
4.09
7.35
6.38
6.6
6.76
6.46
Basic Weighted Avg Shares
88
120
163
167
167
191
222
224
267
262
263
258
Sales/Revenue/Turnover
185
261
284
318
308
339
365
369
299
303
366
365
Operating Margin (%)
26.24
8.65
31.68
33.77
35.27
32.56
25.9
31.36
24.58
24.95
23.07
10.47
Depreciation Expense
- -
- -
4
5
5
10
16
18
20
26
34
- -
Net Income, GAAP
35
12
71
92
93
97
110
110
93
94
95
54
Effective Tax Rate (%)
25.91
53.6
18.66
14.02
15.64
14.67
11.79
12.55
8.39
13.3
8.97
- -
Profit Margin (%)
18.89
4.43
25.14
28.91
30.28
28.48
30.04
29.77
31.24
31.16
25.83
14.8
Working Capital
79
142
195
137
185
702
690
1,242
897
859
850
635
LT Debt
57
- -
- -
- -
- -
8
7
7
10
3
3
3
Total Equity
53
195
281
302
400
933
967
1,697
1,733
1,790
1,843
1,762
Return on Invested Capital (%)
- -
5.41
29.04
31.28
26.15
14.88
11.44
8.27
5.42
5.35
5.22
- -
Return on Capital (%)
- -
7.96
29.36
31.04
26.36
14.41
11.47
8.23
5.45
5.35
5.2
- -
Return on Common Equity (%)
- -
9.39
30.09
31.54
26.59
14.5
11.53
8.25
5.45
5.36
5.2
3.04

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
263
263
263
Market Capitalization
4,909
4,002
3,984

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
921
850
795
Cash, Cash Equivalents & STI
735
680
607
Accounts Receivable, Net
79
73
73
Inventories
38
53
63
Total Current Liabilities
119
187
159
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.45%
17.5%
2.98%
Free Cash Flow
- -
-3.97%
148.88%
Net Income, GAAP
48.52%
-0.02%
0.17%
Sales/Revenue/Turnover
8.03%
2.37%
20.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59
79
81
84
303
2025
78
86
- -
99
366
2026
85
85
97
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.09
0.11
0.09
0.36
2025
0.08
0.08
- -
0.07
0.36
2026
0.06
0.04
0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.07
- -
0.15
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -

Company Description

CEO
Xiao Jun Liu
Full Time Employees
413
Sector
Health technology
Industry
Biotechnology
Address
No. 1-2, No. 31, Niuhe Road Beijing BE China 101407
IPO Date
Jul 27, 2020
Website
scitop.cn
Business
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces and sells probiotic lactic acid bacteria, postbiotics, edible probiotic products, animal and plant microecological preparations and compound food additives primarily in China. The company, founded in 2003 and headquartered in Beijing's Huairou Science City, offers specific strains such as Lacticaseibacillus casei Zhang, isolated from traditional fermented sour mare's milk in Inner Mongolia, which regulates human intestinal flora and prevents upper respiratory tract infections; Bifidobacterium animalis subsp. lactis Probio-M8, derived from breast milk of healthy women, which relieves asthma, acute respiratory infections in infants and regulates immunity; Bifidobacterium animalis subsp. lactis ProSci-246, applied in ready-to-eat probiotic products for weight reduction in obese individuals; and Probio-M9, alongside biotechnology services, consulting and technology transfers. Its products serve the food industry, health medical sector, animal husbandry, agricultural planting and sports nutrition, including as a global strategy partner of China's State General Administration of Sports Training Administration; it targets human, animal and soil health solutions with applications in finished food and beverage products, dietary supplements and biotic ingredients. Beijing Scitop Bio-tech listed on the Shenzhen Stock Exchange's ChiNext Growth Enterprise Market board under ticker 300858.SZ in July 2020, enabling expanded R&D and production capacity; in August 2024, a subsidiary received a 20 million yuan government grant; and in 2025, it commercialized Bifidobacterium animalis subsp. lactis ProSci-246 in market-ready products following scientific validation of its obesity-related benefits, while participating in industry events such as Vitafoods Asia 2025 and Vitafoods Europe 2025.